Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma

Pathology and Oncology Research

Volumn 13, Issue 1, 2007, Pages 57-62

  Rényi, Imre ^a   Bárdi, Edit ^b   Udvardi, Erzsébet ^c   Kovács, Gábor ^d   Bartyik, Katalin ^e   Kajtár, Pál ^f   Masát, Péter ^g   Nagy, Kálmán ^h   Galántai, Ilona ⁱ   Kiss, Csongor ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c Sanofi Synthelabo Co   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e UNIVERSITY OF SZEGED   (Hungary)

^f UNIVERSITY OF PÉCS   (Hungary)

^g Department of Pediatrics   (Hungary)

^h Univ Hosp Borsod Abauj Zemplen Co   (Hungary)

ⁱ Madarász Street Pediatric Hospital   (Hungary)

Author keywords

Leukemia; Lymphoma; Rasburicase; Tumor lysis syndrome; Uric acid

Indexed keywords

ALLOPURINOL; ASPARAGINASE; BICARBONATE; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DAUNORUBICIN; DEXAMETHASONE; PREDNISOLONE; RASBURICASE; STEROID; VINCRISTINE;

ADOLESCENT; ANAPHYLAXIS; ARTICLE; ATOPY; BLOOD CELL COUNT; CALCIUM BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE ESCALATION; FEMALE; HEMODIALYSIS; HUMAN; HYPERURICEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA; MALE; MONOTHERAPY; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PHASE 4 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

EID: 34250000800     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02893442     Document Type: Article

References (11)

1. Goldman SC, Holcenberg JS, Finkleinstein JZ, et al: A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97: 2998-3003, 2001
2. Pui CH, Relling MV, Lascombes F, et al: Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 11: 1813-1816, 1997
3. Pui CH, Mahmoud HH, Wiley JM, et al: Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 19: 697-704, 2001
4. Bosly A, Sonet A, Pinkerton CR, et al: Rasburicase (recombinant urate oxidase) for the management hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 98: 1048-1054, 2003
5. Pession A, Barbieri E: Treatment and prevention of tumor lysis syndrome in children. Experience of Associazione Italiana Ematologia Oncologia Pediatrica. Contrib Nephrol 147:80-92, 2005
6. Schrappe M, Reiter A, Zimmermann M, et al: Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995, Berlin-Frankfurt-Munster. Leukemia 14: 2205-2222, 2000
7. Reiter A, Schrappe M, Parwaresch R, et al: Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage - a report of the Berlin-Frankfurt-Munster Group. Clin Oncol 113: 359-372, 1995
8. Masera G, Jankovic M, Zurlo MG, et al: Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J Pediatr 7: 202-204, 1985
9. Cohen LF, Balow JE, Magrath IT, et al: Acute tumor lysis syndrome: A review of 37 patients with Burkitt lymphoma. Am J Med 68: 486-491, 1980
10. Liu CY, Sims-McCallum RP, Schiffer CA: A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leuk Res 29: 463-465, 2005
11. Annemans L, Moeremans K, Lamotte M, et al: Pan-European multicentre economic evaluation of recombinant urate oxidase (Rasburicase) in prevention and treatment of hyperuricemia and tumor lysis syndrome in haematological cancer patients. Support Care Cancer 11: 249-257, 2003